CORGENTECH REPORTS TRIAL RESULTS FOR 4975 IN HERNIA REPAIR PAIN

A A

Corgentech has reported clinical results from a Phase II trial of 4975, the company's novel, long-acting, non-opioid drug candidate being developed in multiple mid-stage clinical trials for site-specific, moderate-to-severe pain.

The 41-patient, randomized, double-blind, parallel-group, placebo-controlled European study was designed to measure the effectiveness of 4975 in treating pain induced by surgical repair of an inguinal (groin) hernia as measured one and four weeks after surgery.